CoChat

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Introduction: Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes. This trial compared the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian subjects. Methods: In this single-center, double-blind, parallel-group, 13-week trial, 44 healthy male subjects (22 Japanese, 22 Caucasian) were randomized within each race to semaglutide 0.5 mg ( n = 8), 1.0 mg ( n = 8), placebo 0.5 mg ( n = 3) or 1.0 mg ( n = 3). The primary endpoint was semaglutide exposure at steady state [area under the curve (AUC 0–168h )]. Results: Steady-state exposure of semaglutide was similar for both populations: AUC 0–168h estimated race ratio (ERR), Japanese/Caucasian: 0.5 mg, 1.06; 1.0 mg, 0.99; maximum concentration ( C max ) ERR: 0.5 mg, 1.06; 1.0 mg, 1.02. Exposure after the first dose (0.25 mg) was slightly higher in Japanese versus Caucasian subjects (AUC 0–168h ERR 1.11; C max ERR 1.14). Dose-dependent increases in AUC 0–168h and C max occurred in both populations. Accumulation was as expected, based on the half-life ( t 1/2 , ~ 1 week) and dosing interval of semaglutide. Significant body weight reductions were observed with semaglutide 0.5 mg and 1.0 mg in Japanese (both p ≤ 0.05) and Caucasian (both p ≤ 0.05) subjects versus placebo. No new safety issues were identified. Conclusions: The pharmacokinetic, pharmacodynamic, and safety profiles of semaglutide were similar in Japanese and Caucasian subjects, suggesting that no dose adjustment is required for the clinical use of semaglutide in Japanese subjects. Funding: Novo Nordisk A/S, Denmark. Trial registration: ClinicalTrials.gov identifier NCT02146079. Japanese trial registration number JapicCTI-142550.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-018-0677-1

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design. BMI body mass index, PD pharmacodynamic, PK pharmacokinetic, SD single dose, SS steady state
Fig. 1 Study design. BMI body mass index, PD pharmacodynamic, PK pharmacokinetic, SD single dose, SS steady stateCC BY-NC · PubMed Central
Fig. 2 Mean semaglutide profile from first dosing to follow-up. Values are geometric means. From day 7 to day 84 all samples were taken immediately prior to next semaglutide dose (trough samples). All values below the lower limit of quantification are imputed
Fig. 2 Mean semaglutide profile from first dosing to follow-up. Values are geometric means. From day 7 to day 84 all samples were taken immediately prior to next semaglutide dose (trough samples). All values below the lower limit of quantification are imputedCC BY-NC · PubMed Central
Fig. 3 Mean semaglutide profile at steady state: 0–168 h after last dose. Values are geometric means
Fig. 3 Mean semaglutide profile at steady state: 0–168 h after last dose. Values are geometric meansCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 2

  1. International Conference on Harmonisation Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1). 1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E_R1_Guideline.pdf. Accessed Oct 2016.
  2. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60:1390–9. · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk Pharma Ltd. (Japan) (JP)
  • SOUSEIKAI Global Clinical Research Center (JP)
Corresponding author
Ikushima, Ippei
Venue
Advances in Therapy
Published
2018-03-13
Volume
35
Issue
4
Pages
531-544
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2791854127
Cited by
28
References
39
Citations by year
2026: 3 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 2
FWCI
1.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
glucagon-like peptide-1 analogues, pharmacokinetics, pharmacodynamics, racial differences, Japanese subjects, dose proportionality, weight loss, type 2 diabetes, dose adjustment, healthy men
MeSH terms
Semaglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Half-Life, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Weight Loss, Area Under Curve, White People, Asian People, Glucagon-Like Peptide 1, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. https://app.cochat.ai/papers/10.1007/s12325-018-0677-1
The paper
Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018). A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Advances in Therapy. https://doi.org/10.1007/s12325-018-0677-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.